Autolus Therapeutics

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Autolus reports robust Q4 performance, poised for CAR T therapy success

Autolus Therapeutics demonstrated strong operational and financial performance in Q4 2022, supported by key partnerships and successful clinical data for obe-cel.
While facing challenges in competitive positioning and pricing strategy, the company has opportunities to capitalize on upcoming milestones and data releases to drive growth.
By focusing on long-term data integrity and strategic market positioning, Autolus aims to establish obe-cel as a leading therapy in the CAR T landscape.

Autolus Therapeutics reports Q1 loss, highlights CAR T progress

Autolus Therapeutics showcased progress with CAR T programs and a strong financial position
The company's focus on Obe-cel and collaborations with key partners present growth opportunities
Challenges include data disclosure queries, program potential, and partnership considerations
Opportunities lie in extending runway, expanding collaborations, and exploring new indications

Autolus Therapeutics reports strong Q2 results and eyes market expansion

Autolus Therapeutics is on track with its lead program, Obe-cel, and is making strategic moves to enhance its product portfolio and operational capabilities.
The company's financial performance remains stable, with a focus on cost management and extending its cash runway into 2025 through milestone payments.
Despite facing challenges in expense management and regulatory processes, Autolus is well-positioned to capitalize on opportunities in new indications and product development.

Autolus Therapeutics reports strong Q3 earnings and pipeline advancements

Autolus Therapeutics is making significant progress with its pipeline programs, focusing on advancing obe-cel for autoimmune diseases and presenting data at ASH.
The company's strong financial position and anticipated milestones, such as BLA filing and AUTO8 program updates, provide a solid foundation for future growth.
While facing challenges in a competitive market and logistical hurdles for pivotal trials, Autolus has opportunities to differentiate its offerings and strengthen its position in new indications.

Autolus Therapeutics reports strong financials and strategic growth opportunities

Autolus Therapeutics had a successful year financially and operationally, well positioned with a cash reserve for upcoming milestones and program expansions.
While facing regulatory challenges and cost management considerations, the company is strategically focused on expanding its therapeutic opportunities and enhancing operational efficiency.
Opportunities lie in exploring new indications, streamlining patient enrollment processes, and leveraging partnerships for broader market access and growth.

Autolus reports robust Q1 earnings, poised for strategic growth

Autolus Therapeutics demonstrated strong financial performance with increased revenue and cash reserves, positioning the company well for upcoming milestones and commercialization efforts.
While facing challenges related to accounting matters and escalating operating expenses, Autolus remains well-prepared for the launch of obe-cel and future pipeline developments.
Opportunities lie in upcoming regulatory reviews, milestone conferences, and potential treatment regimen evolution in the autoimmune space, signaling a promising outlook for Autolus.

Autolus reports robust Q3 earnings, poised for growth and innovation

Autolus Therapeutics demonstrated strong financial performance and progress in its CAR T therapy programs in Q3 2024, supported by milestone payments and a robust manufacturing facility.
While well-capitalized and positively received by physicians, the company faces challenges in cost guidance, market access strategies, and pediatric trial outcomes.
Opportunities lie in upcoming milestones, pediatric market positioning, and operational efficiency improvements, positioning Autolus for continued growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Jianpu Technology

Wall Street issued positive recommendation ratings for Autolus Therapeutics plc (NASDAQ:AUTL) and Jianpu Technology Inc (NYSE:JT) even though their stocks plunged over the past year through Tuesday, Jan.

Wall Street Recommends Catching These 2 Falling Knives

Alkermes

Atara Biotherapeutics

Innoviva

Retrophin

Here we discuss some biotech stocks, which are down this year so far but have the potential to bounce back next year.

5 Beaten-Down Biotech Stocks Set to Rebound in 2020

Preliminary data on AUTO3 in DLBCL demonstrate safety and feasibilty of CD19 and CD22 dual targeting CAR T

Autolus Therapeutics Announces New Data Showcasing Clinical Progress of AUTO3 in B Cell Malignancies

AUTO1 shows 87% MRD negative complete response in adult patients with r/r ALL, with no severe cytokine release syndrome  

Autolus Therapeutics Announces New Data Showcasing Clinical Progress of Programmed T Cell Therapy Pipeline in Blood Cancers

As of late, it has definitely been a great time to be an investor in Autolus Therapeutics.

Will Autolus Continue to Surge Higher?

LONDON, Nov.  13, 2019  (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, today announced that Dr. Christian Itin, chairman and chief executive officer, will present at the Jefferies 2019 London Healthcare Conference on Wednesday, November 20, 2019 at 10:40 am GMT in London, UK.

Autolus Therapeutics to Present at the Jefferies 2019 London Healthcare Conference

Enhancing the anti-tumor potential of CAR T cells for the treatment of solid tumors Enhancing the anti-tumor potential of CAR T cells for the treatment of solid tumors

Autolus Therapeutics and Noile-Immune Announce Licensing Agreement

Autolus Therapeutics plc (AUTL) CEO Christian Itin on Q3 2019 Results - Earnings Call Transcript

LONDON, Nov.  05, 2019  (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, announced that the United States Food and Drug Administration (FDA) has granted AUTO1 orphan drug designation for treatment of acute lymphoblastic leukemia (ALL) patients.

Autolus Therapeutics Receives FDA Orphan Drug Designation for AUTO1 for Treatment of Acute Lymphoblastic Leukemia

Mirati Therapeutics

Nektar Therapeutics

Due to the explosion in immuno-oncology in recent years, what was once a small scientific meeting near the end of the year has become a go-to event for drug developers.

3 Companies To Watch For At November’s Society for Immunotherapy of Cancer Meeting

Findings from Phase I CARPALL Trial Demonstrate that Autolus’ Novel CAR T Therapy, AUTO1, Induces Enhanced Anti-tumor Response Without Severe Cytokine Release Syndrome

Autolus Announces Publication in Nature Medicine of Data Supporting the Development of AUTO1 for Treatment of Patients with ALL

LONDON, Aug.  28, 2019  (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will participate in the following investor conferences in September:

Autolus Therapeutics to Participate in Upcoming Investor Conferences in September

Autolus Therapeutics plc (AUTL) CEO Christian Itin on Q2 2019 Results - Earnings Call Transcript

Autolus Therapeutics (AUTL) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Autolus Therapeutics (AUTL) in Focus: Stock Moves 8.5% Higher

Autolus Therapeutics PLC. (AUTL) CEO Christian Itin on Q1 2019 Results - Earnings Call Transcript

Autolus Therapeutics (AUTL) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

News for Autolus Therapeutics Stock (AUTL)